Investor Relations
DanCann Pharma A/S was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas.
DanCann Pharma was established due to the poor access for cannabinoid-based drugs and pharmaceuticals shortly after the establishment of the new Pilot Programme with medical cannabis in Denmark.
DanCann Pharma is licensed for handling of euphoriant substances, and during the summer 2018, the Company was licensed as one of the first companies in Denmark to handle and cultivate cannabis for medical use.
DanCann Pharma makes and distributes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis.
Share Information
The company is listed on Spotlight Stock Market and is traded with the ticker name DANCAN (ISIN code DK0061410487. DANCAN TO 1, ISIN code DK0061410560).
Initial Public Offering (2020)
DanCann Pharma A/S was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas.
DanCann Pharma is a Danish public limited company incorporated in Denmark and operating under Danish law.
The Issuer was founded on 20 March 2018 by CEO Jeppe Krog Rasmussen.
Description of DanCann Pharma as of 30 September 2020 see Prospectus below. More information about DanCann Pharma is available under Presentations or in the IPO Teasers. Subscriptions can be made through any of the following platforms:
%402x.svg){kind=icon}
General Meetings
Corporate Governance
DanCann Pharma A/S is a Danish public limited company governed by Danish legislation, mainly the Danish Companies Act and the Danish Annual Accounts Act.
Following the listing of the Company’s shares on Spotlight Stock Market, the Company will apply and adhere to Spotlight Stock Markets’ rules and regulations.
DanCann Pharma's law firm is Mazanti-Andersen.
DanCann Pharma’s auditor is Deloitte, Denmark.
Financial Calendar
Financial Reports
IR Contact
For additional information about DanCann Pharma A/S please contact:
Board of Directors
Jeppe Krog Rasmussen, Founder and CEO at DanCann Pharma since its formation in 2018. Jeppe has been a part of the whole DanCann Pharma journey since its beginning back in March 2018, where he founded the Company. Jeppe is responsible for the strategic direction and operational execution of all processes relevant to DanCann Pharma. In addition to DanCann Pharma Jeppe runs his investment company, JKR Investment Group ApS, where he manages his investment portfolio.
Carsten Trads holds a B.Sc. from Copenhagen Business School, complemented by management training from INSEAD and Harvard Business School.Carsten has more than 30 years international experience within sales, marketing, operations, strategic planning and general management. Executive positions in companies such as Bang & Olufsen A/S, GN ReSound A/S and Plantronics Inc. From 2015 he has been the CEO and owner of C-Plus Consult, assisting small business startups.
Christian Carlsen holds an executive MBA from Henley Business School complemented by management training from INSEAD and Harvard Business School.Christian Carlsen has previously worked for companies such as Bavarian Nordic A/S, Labflex A/S and Novo Nordisk Engineering A/S (NNE). At NNE Christian Carlsen led several strategic projects and activities, including leading an initiative to establish a corporate venture business and establishing a unit with a focus on business model innovation, venture incubation and partnerships.Christian has a long track record of starting, developing and transforming life science and tech companies both in a startup and corporate environment.
Executive Management
Peter Søndergaard holds a Master of Science in Strategy and Management and has more than 15 years of experience from C-level employment in production and sales companies. At DanCann Pharma, Peter Søndergaard will lead the finance function in the growing organization, which consists of DanCann Pharma A/S and the subsidiary CannGros ApS.
Jeppe Krog Rasmussen, Founder and CEO at DanCann Pharma since its formation in 2018. Jeppe has been a part of the whole DanCann Pharma journey since its beginning back in March 2018, where he founded the Company. Jeppe is responsible for the strategic direction and operational execution of all processes relevant to DanCann Pharma. In addition to DanCann Pharma Jeppe runs his investment company, JKR Investment Group ApS, where he manages his investment portfolio.
